Drisis S, El Adoui M, Flamen P, et al. - Through a retrospective analysis of prospectively acquired cohort, nonrandomized, monocentric, diagnostic study of 60 individuals initially enrolled, with 39 women taking part in the final cohort, experts assessed whether parametrical response mapping (PRM)-derived biomarkers could prognosticate early morphological response (EMR) and pathological complete response (pCR) 24–72 hours following the beginning of chemotherapy treatment and whether concentric analysis of nonresponding PRM regions could superiorly prognosticate response. PRM explicated a statistical disparity between pCR response groups. Compared with intermediate and central zones, greater performance for the prognostication of non-pCR was exhibited by peripheral tumor region, nonetheless, the statistical correlation explicated no notable variation. Thus, following the beginning of chemotherapy treatment, PRM could be auspicious of non-pCR 24–72 hours. Furthermore, the peripheral region explicated progressed AUC for non-pCR prognostication and raised signal intensity during treatment for non-pCR tumors, data that could be utilized for optimal tissue sampling.